Annals of Surgical Oncology

, Volume 26, Issue 11, pp 3711–3717 | Cite as

Thyroid and Parathyroid Functions After Pharyngo-Laryngo-Esophagectomy for Cervical Esophageal Cancer

  • Yoshiyuki Saito
  • Hirofumi KawakuboEmail author
  • Hiroshi Takami
  • Junya Aoyama
  • Shuhei Mayanagi
  • Tomoyuki Irino
  • Kazumasa Fukuda
  • Koichi Suda
  • Rieko Nakamura
  • Norihito Wada
  • Yuko Kitagawa
Thoracic Oncology



Cervical esophageal cancer (CEC) patients whose larynx function cannot be preserved often undergo chemoradiotherapy, whereas those with residual or recurrent lesions undergo a pharyngo-laryngo-esophagectomy (PLE); however, some need to undergo a pharyngolaryngectomy with total esophagectomy (PLTE) for synchronous or metachronous esophageal cancer. We retrospectively evaluated the relationship between preoperative irradiation (or the extent of esophageal resection) and postoperative endocrine complications in CEC, including hypothyroidism and hypoparathyroidism.


The cancers of 35 (5.4%) of 678 esophageal cancer patients with esophagectomy treated in 2000–2017 were CECs. We also analyzed the 17 cases of CEC patients who underwent PLE with thyroid lobectomy—11 with irradiation before PLE and 6 without irradiation. Seven patients underwent a PLTE.


Hypothyroidism and hypoparathyroidism occurred in 14 and 12 patients, respectively. The hypothyroidism rate was significantly higher in patients with irradiation versus those without irradiation (100% vs. 50%; p = 0.010), and the hypoparathyroidism rate was significantly higher in the PLTE versus non-PLTE patients (100% vs. 50%; p = 0.026). The mean levothyroxine dosage was 1.60 μg/kg/day in the PLE patients post-irradiation.


Irradiation appears to be a risk factor for hypothyroidism after PLE with thyroid lobectomy, while PLTE might have some effect on hypoparathyroidism. Due to vocal function loss, PLE patients may experience symptoms from endocrine complications. Levothyroxine treatment soon after PLE for post-irradiation patients and patients requiring as-needed calcium or vitamin D supplementation based on biochemical hypocalcemia for PLE (especially PLTE), may be effective in preventing symptomatic endocrine complications.



Yoshiyuki Saito, Hirofumi Kawakubo, Hiroshi Takami, Junya Aoyama, Shuhei Mayanagi, Tomoyuki Irino, Kazumasa Fukuda, Koichi Suda, Rieko Nakamura, Norihito Wada, and Yuko Kitagawa report no conflicts of interest relating to this work.


  1. 1.
    Mendenhall WM, Sombeck MD, Parsons JT, Kasper ME, Stringer SP, Vogel SB. Management of cervical esophageal carcinoma. Semin Radiat Oncol. 1994;4(3):179–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2010. Esophagus. 2017;14(3):189–214.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12(1):1–30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chou S-H, Li H-P, Lee J-Y, Huang M-F, Lee C-H, Lee K-W. Radical resection or chemoradiotherapy for cervical esophageal cancer? World J Surg. 2010;34(8):1832–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Tong DKH, Law S, Kwong DLW, Wei WI, Ng RWM, Wong KH. Current management of cervical esophageal cancer. World J Surg. 2011;35(3):600–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Cao CN, Luo JW, Gao L, et al. Primary radiotherapy compared with primary surgery in cervical esophageal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(10):918–26.CrossRefPubMedGoogle Scholar
  7. 7.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): esophageal and esophagogastric junction cancers (version 4.2107). National Comprehensive Cancer Network; 2017.Google Scholar
  8. 8.
    Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27 Suppl 5:v50–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Ullah R, Bailie N, Kinsella J, Anikin V, Primrose W, Brooker D. Pharyngo-laryngo-oesophagectomy and gastric pull-up for post-cricoid and cervical oesophageal squamous cell carcinoma. J Laryngol Otol. 2002;116(10):826–30.CrossRefPubMedGoogle Scholar
  10. 10.
    Martins AS, Tincani AJ. Thyroidectomy and hypoparathyroidism in patients with pharyngoesophageal tumors. Head Neck. 2006;28(2):135–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Glatstein E, McHardy-Young S, Brast N, Eltringham JR, Kriss JP. Alterations in serum thyrotropin (TSH) and thyroid function following radiotherapy in patients with malignant lymphoma. J Clin Endocrinol Metab. 1971;32(6):833–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Ahn D, Sohn JH, Jeon JH. Hypothyroidism following hemithyroidectomy: incidence, risk factors, and clinical characteristics. J Clin Endocrinol Metab. 2016;101(4):1429–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf). 2004;61(2):232–8.CrossRefGoogle Scholar
  14. 14.
    Paek SH, Lee YM, Min SY, Kim SW, Chung KW, Youn YK. Risk factors of hypoparathyroidism following total thyroidectomy for thyroid cancer. World J Surg. 2013;37(1):94–101.CrossRefPubMedGoogle Scholar
  15. 15.
    So YK, Son Y-I, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148(3):526–31.CrossRefPubMedGoogle Scholar
  16. 16.
    Pattou F, Combemale F, Fabre S, et al. Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J. Surg. 1998;22(7):718–24.CrossRefPubMedGoogle Scholar
  17. 17.
    Tamura K, Shimaoka K, Friedman M. Thyroid abnormalities associated with treatment of malignant lymphoma. Cancer. 1981;47(11):2704–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Nishimura Y, Hiraoka M, Koike R, et al. Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol. 2012;42(9):807–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Verloop H, Louwerens M, Schoones JW, Kievit J, Smit JW, Dekkers OM. Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies. J Clin Endocrinol Metab. 2012;97(7):2243–55.CrossRefPubMedGoogle Scholar
  20. 20.
    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1–122.CrossRefGoogle Scholar
  22. 22.
    De Carlucci D, Tavares MR, Obara MT, Martins LAL, Hojaij FC, Cernea CR. Thyroid function after unilateral total lobectomy: risk factors for postoperative hypothyroidism. Arch Otolaryngol Head Neck Surg. 2008;134(10):1076–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Kojima R, Tsukahara K, Motohashi R, et al. Extent of thyroid resection and thyroid function after postoperative radiotherapy following total laryngectomy or total pharyngo-laryngo-esophagectomy. Int J Clin Oncol. 2017;22(3):438–41.CrossRefPubMedGoogle Scholar
  24. 24.
    Olson B. Integrative approaches to patients undergoing thyroid surgery. In: Roman SA, Sosa JA, Solórzano CC, editors. Management of thyroid nodules and differentiated thyroid cancer. Berlin: Springer; 2017. p. 351–76.CrossRefGoogle Scholar
  25. 25.
    Jonklaas J. Sex and age differences in levothyroxine dosage requirement. Endocr Pract. 2009;16(1):71–9.CrossRefGoogle Scholar
  26. 26.
    Pradeep P, Ramalingam K, Jayashree B. Post total thyroidectomy hypocalcemia: a novel multi-factorial scoring system to enable its prediction to facilitate an early discharge. J Postgrad Med. 2013;59(1):4.CrossRefPubMedGoogle Scholar
  27. 27.
    Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery. 2003;133(2):180–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Olson JA Jr, DeBenedetti MK, Baumann DS, Wells SA Jr. Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. Ann Surg. 1996;223(5):472–8 (discussion 478–80).CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Thompson N, Eckhauser F, Harness J. The anatomy of primary hyperparathyroidism. Surgery. 1982;92(5):814–21.PubMedGoogle Scholar
  30. 30.
    Athanasopoulos PG, Kyriazi M, Arkadopoulos N, et al. Parathyroid autotransplantation in extensive head and neck resections: case series report. World J Surg Oncol. 2011;9(1):149.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bourquin E. How to anticipate psychological suffering. J Nurs Educ Pract. 2014;4(4):99.Google Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Yoshiyuki Saito
    • 1
  • Hirofumi Kawakubo
    • 1
    Email author
  • Hiroshi Takami
    • 2
  • Junya Aoyama
    • 1
  • Shuhei Mayanagi
    • 1
  • Tomoyuki Irino
    • 1
  • Kazumasa Fukuda
    • 1
  • Koichi Suda
    • 1
    • 3
  • Rieko Nakamura
    • 1
  • Norihito Wada
    • 1
  • Yuko Kitagawa
    • 1
  1. 1.Department of Surgery, School of MedicineKeio UniversityTokyoJapan
  2. 2.Department of SurgeryIto HospitalTokyoJapan
  3. 3.Division of Upper GI, Department of SurgeryFujita Health UniversityToyoakeJapan

Personalised recommendations